文献速递产科母胎医学

四硝酸季戊四醇酯改善子宫灌注受损孕妇所生儿童的结局:双盲随机PETN试验的12个月随访与安全性数据

Pentaerythrityl tetranitrate improves the outcome of children born to mothers with compromised uterine perfusion-12-months follow-up and safety data of the double-blind randomized PETN trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2024-03-07

本文为四硝酸季戊四醇酯(PETN)随机对照多中心试验的随访研究,报告240名12月龄儿童及144名入住新生儿重症监护病房新生儿的结局。12月龄时PETN组无发育损伤且年龄适宜发育的儿童显著更多(P=.018),慢性病存在率更低(P=.041);新生儿重症监护病房结局两组无差异,不良事件数量与性质两组无差异。

要点

  • 12月龄时PETN组无发育损伤且年龄适宜发育的儿童显著多于安慰剂组(P=.018)。
  • PETN组慢性病存在率低于安慰剂组(P=.041)。
  • 144名入住新生儿重症监护病房的新生儿结局及不良事件两组无差异。

核心结论

  • 分析显示PETN队列所生儿童在12月龄时较安慰剂组具有明显优势,表现为无慢性病的正常发育发生率增加。
  • 安全性已得到证实,但需进一步随访研究以证明对子宫灌注受损妊娠进行PETN治疗的合理性。

研究设计与样本

  • 本研究为PETN随机对照多中心试验的随访研究。
  • PETN试验为随机、双盲、安慰剂对照研究,旨在评估一氧化氮供体四硝酸季戊四醇酯在胎盘灌注异常妊娠中预防胎儿生长受限和围产期死亡的有效性与安全性。
  • 随访纳入240名12月龄儿童,收集身高、体重、头围、发育里程碑、慢性病存在情况,并纳入试验期间入住新生儿重症监护病房的144名新生儿。

主要发现

  • 12月龄时PETN组无发育损伤且年龄适宜发育的儿童显著多于安慰剂组(P=.018)。
  • PETN组慢性病存在率低于安慰剂组(P=.041)。
  • 144名入住新生儿重症监护病房的新生儿结局数据未显示治疗组与安慰剂组间差异。
  • 两组报告的不良事件数量与性质无差异。

局限性

  • 原文结论指出需进一步随访研究以证明对子宫灌注受损妊娠进行PETN治疗的合理性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This is a follow-up study to the pentaerythrityl tetranitrate randomized controlled multicenter trial that reports neonatal outcome data of newborns admitted to neonatal intensive care units and outcome data of the offspring at 12 months of age. OBJECTIVE: We present data on adverse events reported during the study to document the safety of pentaerythrityl tetranitrate treatment during pregnancy. To further evaluate the effects of pentaerythrityl tetranitrate on neonatal and long-term outcomes, we present follow up data from of 240 children at 12 months of age, including information on height, weight, head circumference, developmental milestones, and the presence of chronic disease and of 144 newborns admitted to the neonatal intensive care unit during the trial. STUDY DESIGN: The pentaerythrityl tetranitrate trial was a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of the nitric oxide-donor pentaerythrityl tetranitrate in the prevention of fetal growth restriction and perinatal death in pregnancies complicated by abnormal placental perfusion. RESULTS: Results at 12 months demonstrated that significantly more children were age appropriately developed without impairments in the pentaerythrityl tetranitrate group (P=.018). In addition, the presence of chronic disease was lower in the pentaerythrityl tetranitrate group (P=.041). Outcome data of the 144 newborns admitted to the neonatal intensive care unit did not reveal differences between the treatment and placebo groups. There were no differences in the number or nature of reported adverse events between the study groups. CONCLUSION: The analysis shows that study children born in the pentaerythrityl tetranitrate cohort have a clear advantage compared with the placebo group at the age of 12 months, as evidenced by the increased incidence of normal development without the presence of chronic disease. Although safety has been proven, further follow-up studies are necessary to justify pentaerythrityl tetranitrate treatment during pregnancies complicated by impaired uterine perfusion.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Groten T, Lehmann T, Städtler M, et al. Pentaerythrityl tetranitrate improves the outcome of children born to mothers with compromised uterine perfusion-12-months follow-up and safety data of the double-blind randomized PETN trial. Am J Obstet Gynecol MFM. 2024. PMID: 38460823. doi:10.1016/j.ajogmf.2024.101332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。